Skip to search formSkip to main contentSkip to account menu

Afatinib

Known as: (2E)-N-(4-(3-chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide, 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)- 6-quinazolinyl)-4-(dimethylamino)-, (2E)-, Afatinibum 
An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB… 
National Institutes of Health

Related topics

Related topics

15 relations
Afatinib 20 MG Oral TabletAfatinib 40 MG Oral TabletAfatinib 40 MG Oral Tablet [Gilotrif]EGFR protein, human

Narrower (2)

BIBW 2992BIBW-2992-MA2

Broader (2)

QuinazolinesRadiation-Sensitizing Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
INTRODUCTION Exon 18-T719X EGFR mutation in non-small cell lung cancer is rare, only 1-5% of all EGFR mutations. The efficacy of… 
2017
2017
A Case of Patient with Recurring Non-Small Cell Lung Carcinoma Treated with Samchilchoongcho-Jung in Conjunction with Afatinib
Objective: The purpose of this study is to report the case of a patient with recurring non-small cell lung carcinoma (NSCLC… 
2017
2017
Abstract 3554: The combined effect of afatinib and metformin on glycolytic regulation in EGFR-mutant non-small cell lung cancer
Background: The metabolic features of cancer cells allows their rapid proliferation and escape from apoptosis. Novel targeted… 
2016
2016
Quantitative analysis of HER family proteins using mass spectrometry as a predictive tool of response to anti-HER therapies in breast cancer
Introduccion: La expresion desregulada y la actividad de los miembros de la familia HER es frecuente en el cancer de mama (CM… 
2013
2013
Overcoming acquired resistance to gefitinib in NSCLC with EGFR T790M mutation using combination of afatinib and cetuximab
Objective: To investigate the effect of afatinib combined with cetuximab on the acquired resistance in NSCLC (non-small cell lung… 
2013
2013
DIVERGENT ACTIVITY OF AFATINIB (AFAT) AND CETUXIMAB (CET) IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF ACQUIRED ERLOTINIB RESISTANCE.
Abstracts Journal of Thoracic Oncology • Volume 8, Supplement 2, November 2013 Conclusion: We have performed broad proteomic… 
2013
2013
Afatinib (Giotrif®) for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)
Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and is therefore one of the leading causes of… 
2012
2012
Personalización del tratamiento del cáncer de pulmón de células no pequeñas
A. Mujer de 58 anos de edad con antecedentes heredo-familiares de cancer de tiroides en hermana. Tabaquismo desde los 20 a los 30… 
2012
2012
Abstract OT1-1-14: Open-label, Phase II trial of afatinib, with or without vinorelbine, for the treatment of HER2-overexpressing inflammatory breast cancer (IBC)*
Background: IBC is a rare but aggressive form of BC accounting for 1–5% of all BC. Despite recent treatment advances, prognosis… 
2012
2012
Abstract OT1-1-16: LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC…
Background: Afatinib is a ErbB Family Blocker that irreversibly blocks signaling from all relevant ErbB Family dimers. Afatinib…